medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2013, Number 3

<< Back Next >>

Acta Ortop Mex 2013; 27 (3)

Origin of surgical metastatic bone disease

Sánchez-Torres LJ, Ruiz-Tenorio A, Chávez-Reyna MM, Rodríguez-Domínguez EA, Rascón-Álvarez O, Santos-Hernández M

Language: Spanish
References: 37
Page: 190-196
PDF size: 256.69 Kb.


ABSTRACT

Background: Metastatic bone disease should be considered as a public health problem. The alterations it may cause include pain that is refractory to medical treatment, metabolic instability, pathologic fractures and spinal disorders. Material and methods: The primary tumor site that led to the need for surgery was investigated in a series of patients with a diagnosis of metastatic bone disease. The bone involved and the histology of the lesions were also studied. Results: Kidney cancer was the one that most frequently required a surgical procedure; it was followed by breast and prostate cancer. The primary tumor was not found in 6.36% of cases. The bones affected by the lesions studied were as follows in order of occurrence: femur, spine, humerus and pelvis. Adenocarcinoma was the most frequent histological diagnosis. Discussion: The diagnosis of metastatic bone disease should always be considered in patients over forty years of age with skeletal lesions, preferably lytic. Conclusions: In this study, kidney cancer, the proximal limbs and adenocarcinomas were the variables that most frequently produced metastatic bone lesions that warranted a surgical procedure.


REFERENCES

  1. Salazar PR, Axotla BVM, Parra GA: Metástasis óseas en tumores malignos de la mama. Breve informe epidemiológico. Rev Mex Ortop Traum. 2002; 16(2): 51-5.

  2. Talbot M, Turcotte RE, Isler M, Normandin D, Iannuzzi D, Downer P: Function and healt status in surgically treated bone metastases. Clin Orthop Relat Res. 2005; 438: 215-20.

  3. Vicent S y cols: Las metástasis óseas del cáncer. An Sist Sanit Navar. 2006; 29(2): 177-87.

  4. Lipton A: Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol. 2004; 2(3): 205-20.

  5. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double – blind, randomized trial – The zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 2003; 21: 3150-7.

  6. Coleman RE: Management of bone metastases. Oncologist. 2000; 5: 463-70.

  7. Chrapko BE, Nocun A, Golebiewska R, Jankowska H, Zaorska-Rajca J: Bone turnover markers and bone scintigraphy in the evaluation of skeletal metastases. Nucl Med Rev Cent East Eur. 2005; 8(2): 100-4.

  8. Bell R: Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist. 2005; 10(Suppl 1): 8-13.

  9. Choong PFM: The molecular basis of skeletal metastases. Clin Orthop Relat Res. 2003; 415S: S19-S31.

  10. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12 (Suppl 20): S6243-9.

  11. Harrington KD: Impending pathologic fractures from metastatic malignancy: Evaluation and management. Instr Course Lect. 1986; 35: 357-81.

  12. Damron TA, Morgan H, Prakash D, Grant W, Aronowitz J, Heiner J: Metastatic disease of long bones. Critical evaluation of Mirels’ rating system for impending pathologic fractures. Clin Orthop Relat Res. 2003; 415 S: S201-7.

  13. Mirels H: Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989; 249: 256-64.

  14. Evans AR, Bottros J, Grant W, Chen BY, Damron TA: Mirels’ rating for humerus lesions is both reproducible and valid. Clin Orthop Relat Res. 2008; 466: 1279-84.

  15. Osborne RL: The differential radiologic diagnosis of bone tumors. CA Cancer J Clin. 1974; 24: 194-211.

  16. Unni KK: Conditions that commonly simulate primary neoplasms of bone. In: Dahlin’s Bone Tumors. General aspects and data on 11,087 cases. Lippincot – Raven Publishers; USA 1996: 355-432.

  17. Wodajo FM, Gannon FH, Murphey MD: Metastatic carcinoma. In: Visual guide to musculoskeletal tumors. A clinical – radiologic – histologic approach. Saunders Elsevier; USA 2010: 134-9.

  18. Greenspan A, Jundt G, Remagen W: Metastases. In: Differential diagnosis in orthopaedic oncology. Lippincott Williams & Wilkins; USA 2007: 458-80.

  19. Jacofsky DJ, Frassica DA, Frassica FJ: Metastatic disease to bone. Hosp Physician. 2004; 39: 21-8.

  20. Rougraff BT, Kneisl JS, Simon MA: Skeletal metastases of unknown origin. J Bone Joint Surg Am. 1993; 75-A (9): 1276-81.

  21. Jacobsen S, Stephensen SL, Paaske BP, Lie PG, Lausten GS: Skeletal metastases of unknown origin: a retrospective analysis of 29 cases. Acta Orthop Belg. 1997; 63(1): 15-22.

  22. Rougraff BT: Diagnosis of bone metastases. Evaluation of the patient with carcinoma of unknown origin metastatic to bone. Clin Orthop Relat Res. 2003; 415S: S105-9.

  23. Tsukushi S, Katagiri H, Kataoka T, Nishida Y, Ishiguro N: Serum tumor markers in skeletal metastasis. Jpn J Clin Oncol. 2006; 36(7): 439-44.

  24. Frassica FJ, Frassica DA: Metastatic bone disease: general considerations. In: Menendez LR: Orthopaedic Knowledge Update. Musculoskeletal tumors. American Academy of Orthopaedic Surgeons. First edition. Musculoskeletal Tumor Society; USA 2002: 305-12.

  25. Sherry HS, Levy RN, Siffert RS: Metastatic disease of bone in orthopedic surgery. Clin Orthop Relat Res. 1982; 169: 44-50.

  26. Resnick D: Metástasis esqueléticas. En: Huesos y articulaciones en imagen. Segunda Edición. Marbán; España1998: 1076-91.

  27. Fechner RE, Mills SE: Metastatic tumors involving bone. In: Tumors of the bone and joints. Atlas of tumor pathology. Armed Forces Institute of Pathology; USA 1993: 245-52.

  28. Mundy GR, Yoneda T: Facilitation and suppression of bone metastasis. Clin Orthop Relat Res. 1995; 312: 34-44.

  29. Weber KL, Gebhardt MC: What’s new in musculoskeletal oncology. Specialty update. J Bone Joint Surg Am. 2003; 85-A(4): 761-7.

  30. Galasko CSB: Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res. 1982; 169: 20-7.

  31. Rouleau PA, Wenger DE: Radiologic evaluation of metastatic bone disease. In: Menendez LR: Orthopaedic knowledge Update. Musculoskeletal tumors. American Academy of Orthopaedic Surgeons. First edition. Musculoskeletal Tumor Society; USA 2002: 313-22.

  32. Sanders TG, Parsosns III TW: Radiographic imaging of musculoskeletal neoplasia. Cancer Control. 2001; 8(3): 221-31.

  33. Dorfman HD, Czerniak B: Metastatic tumors in bone. In: Bone tumors. Mosby; 1998: 1009-40.

  34. Boland PJ, Lane JM, Sundaresan N: Metastatic disease to the spine. Cin Orthop Relat Res. 1982; 169: 95-102.

  35. Mandell GA: Radionuclide imaging. In: Kricun ME: Imaging of bone tumors. W.B. Saunders Company; USA 1993: 504-67.

  36. Mettler FA Jr, Guiberteau MJ: Skeletal system. In: Essentials of nuclear medicine imaging. Fourth edition. Saunders; USA 1998; 11: 285-333.

  37. Schachar NS: An update on the nonoperative treatment of patients with metastastic bone disease. Clin Orthop Relat Res. 2001; 382: 75-81.




2020     |     www.medigraphic.com